ES2063033T3 - Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. - Google Patents

Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.

Info

Publication number
ES2063033T3
ES2063033T3 ES88303855T ES88303855T ES2063033T3 ES 2063033 T3 ES2063033 T3 ES 2063033T3 ES 88303855 T ES88303855 T ES 88303855T ES 88303855 T ES88303855 T ES 88303855T ES 2063033 T3 ES2063033 T3 ES 2063033T3
Authority
ES
Spain
Prior art keywords
igf
treatment
bone diseases
bone
osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88303855T
Other languages
English (en)
Inventor
David J Baylink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878710676A external-priority patent/GB8710676D0/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Application granted granted Critical
Publication of ES2063033T3 publication Critical patent/ES2063033T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LOS PEPTIDOS QUE INCLUYEN EL FACTOR DE CRECIMIENTO RELACIONADO CON LA INSULINA-II (IGF-II) SON UTILES EN EL TRATAMIENTO DE ALTERACIONES OSEAS TALES COMO LA OSTEOPOROSIS. PUEDEN SER ADMINISTRADOS COMO EL UNICO INGREDIENTE ACTIVO DE UNA COMPOSICION FARMACOLOGICA O EN COMBINACION CON UN AGENTE LOCALIZADOR OSEO TAL COMO EL FLUORURO SODICO, CON EL QUE TIENE EN EFECTO SINERGISTICO.
ES88303855T 1987-04-28 1988-04-28 Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. Expired - Lifetime ES2063033T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4362887A 1987-04-28 1987-04-28
GB878710676A GB8710676D0 (en) 1987-05-06 1987-05-06 Pharmacologically active peptides

Publications (1)

Publication Number Publication Date
ES2063033T3 true ES2063033T3 (es) 1995-01-01

Family

ID=26292207

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88303855T Expired - Lifetime ES2063033T3 (es) 1987-04-28 1988-04-28 Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.

Country Status (4)

Country Link
EP (1) EP0289314B1 (es)
AT (1) ATE112684T1 (es)
DE (1) DE3851776T2 (es)
ES (1) ES2063033T3 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962639A (en) 1987-11-06 1999-10-05 Washington Research Foundation Synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites
US6153732A (en) * 1987-11-06 2000-11-28 Washington Research Foundation Kit for detecting analyte indicative of type II collagen resorption in vivo
US5702909A (en) * 1987-11-06 1997-12-30 Washington Research Foundation Methods of detecting collagen type II degradation in vivo
US6027903A (en) * 1987-11-06 2000-02-22 Washington Research Foundation Kit for detecting analyte indicative of type I collagen resorption in vivo
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
JPH03151877A (ja) * 1989-06-02 1991-06-28 Chiron Corp 骨カルシウム沈着因子
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2020729A1 (en) * 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
DK27390D0 (da) * 1990-02-02 1990-02-02 Troels Torp Andreassen Fremgangsmaade og apparat til administration af biologisk aktive stoffer
JP2527896B2 (ja) * 1991-04-19 1996-08-28 ベーリンガー・マンハイム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒト骨由来インスリン様成長因子結合タンパク
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (es) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
DE69835878T2 (de) * 1997-05-05 2007-04-26 Mayo Foundation For Medical Education And Research, Rochester IGFIIE/ IGFBP2 Komplex
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7041314B2 (en) 2001-05-24 2006-05-09 Neuren Pharmaceuticals Ltd. GPE analogs and peptidominetics
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DE3343253A1 (de) * 1983-08-11 1985-02-21 Neill Bailey San Antonio Tex. Walsdorf Fluorid-tablette mit verzoegerter wirkstoff-freigabe und verfahren zu ihrer herstellung
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Also Published As

Publication number Publication date
DE3851776D1 (de) 1994-11-17
DE3851776T2 (de) 1995-05-04
ATE112684T1 (de) 1994-10-15
EP0289314A3 (en) 1990-11-22
EP0289314B1 (en) 1994-10-12
EP0289314A2 (en) 1988-11-02

Similar Documents

Publication Publication Date Title
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
ES2106735T3 (es) Tratamiento de desordenes mediante la aplicacion de factores de crecimiento de tipo de insulina y analogos.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
GR3007202T3 (es)
ES2106794T3 (es) Utilizacion del inositol-trifosfato para el tratamiento de inflamaciones.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
ES2060775T3 (es) Egf para la prevencion de daños en tejidos despues de un episodio isquemico.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
ES2039773T3 (es) Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
ES2194513T3 (es) Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DE3773893D1 (de) Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 289314

Country of ref document: ES